- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01235429
Partners in Care Diabetes Self-management Intervention
Specific Aim 3: Partners in Care Randomized Controlled Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a feasibility study using a randomized controlled trial (RCT) design in which 100 Native Hawaiians (NHs) and other Pacific Islanders (PPs) will be randomized to either a 3-month diabetes self-management group (DSMG; N=50) or a delayed intervention control group (CG; N=50). Participants in the DSMG will receive culturally-tailored, group diabetes self-management education delivered in a community setting by trained community peer educators. To meet this objective, we have partnered with four community-based organizations: 1) Hawai'i Maoli Association of Hawaiian Civic Clubs, 2) Ke Ola Mamo Native Hawaiian Health Care System, 3) Kokua Kalihi Valley Comprehensive Family Services, and 4) Kula No Nā Po'e Hawai'i. These four organizations provide services to a large number of Pacific People to include, but not limited to, Native Hawaiians, Samoans, Filipinos, and Chuukese. They already have intervention research experience as members of the PILI 'Ohana CBPR Project. The 3-month face-to-face intervention will be community-based and community-led by trained community peer educators from these four partnering community organizations. Individuals with a hemoglobin A1c (HbA1c; average blood sugar levels) >=8% will be recruited for the study because they represent the most at-risk for diabetes-related complications.
Over a 1-year accrual period, the community partners will recruit and enroll 100 eligible NHs and PPs (25 participants per a participating community), as well as deliver and evaluate the intervention in their respective community settings. The primary outcomes of our study are hemoglobin A1c and self-reported diabetes specific quality of life. Secondary outcomes are cholesterol levels (including HDL, LDL, total cholesterol, and triglycerides), blood pressure, body mass index, and psychosocial adaptation.
Type d'étude
Inscription (Anticipé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Hawaii
-
Honolulu, Hawaii, États-Unis, 96813
- University of Hawaii
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Self-reported Native Hawaiian, Filipino, or other Pacific Islander ethnic background,
- Adults age >=18 years,
- English-speaking,
- Physician-diagnosed type 2 diabetes, and
- Baseline hemoglobin A1c >=8%
Exclusion Criteria:
- Survival less than 6 months,
- Planning to move off island or out of state during the study period,
- Pregnancy,
- Any co-morbid condition (physical and mental disabilities) that would prevent the individual from participating in the intervention protocol (i.e., major psychiatric illness).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Educational
Participants will receive 12 diabetes self-management educational lessons in a small group setting located within the participating communities and delivered by trained community health workers.
|
Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
Diabetes self-management education
|
Comparateur actif: Delayed education
The delayed education group will receive the same intervention after the intervention group has completed the educational lessons and all participants have completed the follow-up assessments.
|
Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
Diabetes self-management education
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
hemoglobin A1c
Délai: 3 months
|
Hemoglobin A1c will be assessed at baseline and post intervention in the intervention and delayed intervention participants.
|
3 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Quality of life
Délai: 3 months
|
Quality of life using the Problem Areas in Diabetes survey will be assessed at baseline and post intervention in the intervention and delayed intervention participants.
|
3 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Joseph K Kaholokula, PhD, University of Hawaii
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PILI ARRA Supplement
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète de type 2
-
Bnai Zion Medical CenterInconnue
-
Jiangsu HengRui Medicine Co., Ltd.Complété
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Pas encore de recrutement
-
Endogenex, Inc.Pas encore de recrutementDiabète sucré, Type 2 | Diabète | Diabète sucré de type 2 | Diabète de type 2 | Diabète de type 2
-
Jeil Pharmaceutical Co., Ltd.Pas encore de recrutementDiabète sucré de type 2Corée, République de
-
Nanjing First Hospital, Nanjing Medical UniversityRecrutement
-
Nanjing First Hospital, Nanjing Medical UniversityRecrutement
-
Xiangya Hospital of Central South UniversityRecrutement
-
HighTide Biopharma Pty LtdActif, ne recrute pas
Essais cliniques sur Partners in Care
-
University of AlbertaPublic Health Agency of Canada (PHAC)Complété
-
Guy's and St Thomas' NHS Foundation TrustB&D ElectromedicalComplétéEffondrement dynamique excessif des voies respiratoires | TrachéobronchomalacieRoyaume-Uni
-
National Hospital for Tropical Diseases, Hanoi,...ComplétéMéningite cryptococciqueViêt Nam
-
University of ArizonaInconnuePneumothorax traumatiqueÉtats-Unis
-
Silke Wiegand-Grefe, Prof. Dr.Charite University, Berlin, Germany; Hannover Medical School; University Hospital... et autres collaborateursActif, ne recrute pasMaladies raresAllemagne
-
HK inno.N CorporationInconnue
-
Medical University InnsbruckBarmherzige Brüder Vienna; Tiroler Landeskrankenanstalten GmbH (TILAK); Tiroler... et autres collaborateursComplétéAccident vasculaire cérébral | Attaque ischémique, transitoire | L'analyse coûts-avantages | Prévention secondaire | Gestion des maladiesL'Autriche
-
Johnson & Johnson Vision Care, Inc.ComplétéAcuité visuelle, biomicroscopie à la lampe à fente (évaluation de la coloration cornéenne)États-Unis
-
Chung Shan Medical UniversityComplétéSoignant | Patient d'AVCTaïwan
-
Elizabeth Glaser Pediatric AIDS FoundationUnited States Agency for International Development (USAID); Ministry of Health...Complété